Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
about
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Beyond taxanes: the next generation of microtubule-targeting agentsIxabepilone development across the breast cancer continuum: a paradigm shift.Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patientsRandomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCAntitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cellsSustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.Treatment options for breast cancer resistant to anthracycline and taxanePhase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.Microtubule stabilising agents for cancer chemotherapy.Ixabepilone for the treatment of endometrial cancer.Azaepothilone B and its derivatives: a patent review.Epothilone B Speeds Corneal Nerve Regrowth and Functional Recovery through Microtubule Stabilization and Increased Nerve Beading.Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment.
P2860
Q26781365-200352DA-ED7E-4C15-A7E4-4F837410D05FQ26865369-2B93B228-BA4C-451F-8354-904AAE4F71C6Q34417996-3002770B-8403-4847-A265-58811E94FE98Q34562783-46F84455-5AE5-4BF2-9243-0F58F836466BQ35847455-FF2B9F59-9533-446E-A329-B1764EAEF586Q36457669-1E2E5F94-B394-4DBF-B172-DEA3511BEDB8Q36963585-43212E06-10BB-421E-A2C2-BC24EB4EBFA4Q37207961-C28CC0F1-B999-4DEB-85D7-172B539A46D3Q37278360-D6314F8A-1FFB-48BD-ADFC-EFEF0C340BD6Q37481355-B98939B1-C1CE-4754-973A-B67303020432Q38763500-2CD5D359-50C2-454C-AE46-E0A8174D9F2EQ38860410-08449A94-D2A4-4768-82B8-0E64BE61BE04Q49483504-5D2657C7-FB29-4C81-A778-435C90FB5AEDQ53800820-97F511BD-8240-4071-86F3-46BBD8C084E3
P2860
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@en
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@nl
type
label
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@en
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@nl
prefLabel
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@en
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@nl
P1433
P1476
Ixabepilone: a novel antineopl ...... e tumor resistance mechanisms.
@en
P2093
Linda Vahdat
P304
P356
10.1634/THEONCOLOGIST.2007-0167
P577
2008-03-01T00:00:00Z